Powered by
Intec Pharma Initiates Phase I Trial of Accordion Pill for Cannabinoid Therapies

Expects Phase I Results in the Third Quarter of 2017

Intec Pharma Ltd. (Nasdaq; TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill(TM) platform technology, announces the initiation of a Phase I clinical trial of AP-CBD/THC, its Accordion Pill platform with the two primary cannabinoids contained inCannabis sativa,cannabidiol (CBD) and tetrahydrocannabinol (THC), which is being developed by Intec for various indications

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox